Castle biosciences stock.

Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend.Jul 13, 2023 · Shares of Castle Biosciences ( CSTL -7.22%) were down more than 20.2% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence. The healthcare stock closed ... Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Find real-time CSTL - Castle Biosciences Inc stock quotes, company profile, news and forecasts from CNN Business. 1 Nis 2022 ... TAKEAWAY: 48% Chance Of Rise Over Next 1M For CSTL · CSTL Stock's Historical Performance Compared · How has Castle Biosciences (CSTL) stock price ...

Castle Biosciences is the only provider of 31-GEP testing, and all testing is performed in a College of American Pathologists/Clinical Laboratory Improvement Amendments–certified laboratory. We evaluated the ability of the 31-GEP to stratify risk in MSS and overall survival (OS) to confirm the prognostic ability of the 31-GEP at the …

Dec 1, 2023 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study in the Journal of the Advanced Practitioner in Oncology (JADPRO) that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.

10. HealthQuest Capital joined the board of directors in 2014. In 2014, Castle Biosciences landed $11.8 million during a financing round led by new investor HealthQuest Capital. In return for its contribution, Healthquest was given a place on the company’s board of directors.Key Insights Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their...Innovators With A Proven Track Record of Success. An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. Jun 5, 2023 · According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00. Nov 17, 2023 · 4 Wall Street research analysts have issued 1-year price targets for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $41.00. On average, they anticipate the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 64.4% from the stock's current price.

Europe PMC is an archive of life sciences journal literature. https://orcid.org

The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol “CSTL.” All of the common stock in the offering is being ...

Castle Biosciences-stock Castle Biosciences Inc Registered Shs Stock , CSTL 19.78 + +% After-market 04:20:00 PM NAS Add to watchlist 19.78 -0.10 -0.50% Official Close …Castle Learning Online’s products don’t come with ready-made answer keys, but they do provide instant feedback and answers once the student has gone through an assignment.Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ...Castle Biosciences is registered under the ticker NASDAQ:CSTL . Their stock opened with $16.00 in its Jul 24, 2019 IPO. Castle Biosciences is funded by 11 investors. Spindletop Capital Management and BrightEdge Fund are the most recent investors. Castle Biosciences has acquired 3 organizations. Their most recent acquisition was AltheaDx …Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating …

Castle Biosciences today announced it has signed a definitive agreement to acquire Cernostics, Inc. ... which may consist entirely of cash or $20 million in cash and $10 million in common stock of ...Key Insights. Significantly high institutional ownership implies Castle Biosciences' stock price is sensitive to their trading actions. 51% of the business is held by the top 12 shareholdersCastle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ...Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …All earnings call transcripts on Castle Biosciences, Inc. (CSTL) stock. Read or listen to the conference call. Download the investor presentation - earnings ...CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 820 S. Friendswood Drive, Suite 201, Friendswood, Texas 77546 (Address of principal executive offices) (Zip Code) (866) 788-9007A stay in one of the world’s most beautiful castle hotels is truly a once-in-a-lifetime experience. These days, you don’t have to be born a royal to live like one, which is why we’ve rounded up some of the best castles in the world that you...

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... Leadership: Castle Biosciences. Stock and Other Ownership Interests: Castle Biosciences. Patents, Royalties, Other Intellectual Property: Patents with Castle Biosciences. No other potential conflicts of interest were reported. OPTIONS & TOOLS. Export Citation: Track Citation: Add To Favorites: Rights & Permissions; COMPANION …Simply Wall St. June 8, 2023 at 3:34 AM · 3 min read. The Castle Biosciences, Inc. ( NASDAQ:CSTL) share price has fared very poorly over the last month, falling by a substantial 34%. Instead of ...Castle Biosciences is forecast to grow earnings and revenue by 32.8% and 14.8% per annum respectively. EPS is expected to grow by 32.1% per annum. Return on equity is forecast to be -26.8% in 3 years.Dec 1, 2023 · CSTL Earnings Date and Information. Castle Biosciences last released its earnings results on November 2nd, 2023. The reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.66. The company earned $61.49 million during the quarter, compared to the consensus estimate of $44.94 million. The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days.

Mr. Harrison CSTL stock SEC Form 4 insiders trading. Miles has made over 2 trades of the Castle Biosciences stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,825 units of CSTL stock worth $76,041 on 2 June 2023.. The largest trade he's ever made was exercising 3,825 units of Castle Biosciences …

Castle Biosciences Inc Stock Price History. Castle Biosciences Inc’s price is currently up 15.45% so far this month. During the month of July, Castle Biosciences Inc’s stock price has reached a high of $20.96 and a low of $13.18. Over the last year, Castle Biosciences Inc has hit prices as high as $36.10 and as low as $9.26. Year to date ...

What exchange does Castle Biosciences trade on and what is the company’s stock symbol? Castle Biosciences’ stock is traded on The Nasdaq Global Market under the ticker symbol "CSTL". Castle Biosciences Market Cap: 537.40M, Enterprise value: 484.98M, P/E: -8.76, PEG ratio: 0.08, EPS: -2.84, Revenue: 192.00M, EBITDA: -64.35M, ...Insiders trading at Castle Biosciences. Over the last 4 years, insiders at Castle Biosciences have traded over $369,408,068 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold, and Joseph C. Iii Cook.On average, Castle …At Castle Biosciences, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of …The estimated Net Worth of Kristen M Oelschlager is at least $2.3 Million dollars as of 28 December 2022. Ms. Oelschlager owns over 7,178 units of Castle Biosciences stock worth over $1,593,448 and over the last 2 years she sold CSTL stock worth over $710,200. In addition, she makes $0 as Senior Vice President - Clinical …Dec 4, 2023 · Castle Biosciences stock opened at $19.97 on Monday. The firm has a market capitalization of $537.39 million, a P/E ratio of -7.03 and a beta of 0.97. The company has a 50-day simple moving ... Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... Castle Biosciences Inc’s trailing 12-month revenue is $192.0 million with a -39.3% profit margin. Year-over-year quarterly sales growth most recently was 66.2%. Analysts expect adjusted earnings to reach $-2.723 per share for the current fiscal year. Castle Biosciences Inc does not currently pay a dividend.These 4 analysts have an average price target of $38.75 versus the current price of Castle Biosciences at $22.02, implying upside. Below is a summary of how these 4 analysts rated Castle ...

Discover historical prices for CSTL stock on Yahoo Finance. View daily, weekly or monthly format back to when Castle Biosciences, Inc. stock was issued.In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...In the last 3 months, 12 analysts have offered 12-month price targets for Castle Biosciences. The company has an average price target of $34.83 with a high of $41.00 and a low of $25.00.Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ...Instagram:https://instagram. best information technology etfnasdaq etf listbest stock under dollar10half dollar worth According to 7 analyst offering 12-month price targets in the last 3 months, Castle Biosciences has an average price target of $35.14 with a high of $41.00 and a low of $25.00.Jun 2, 2023 · Shares of Castle Biosciences ( CSTL 0.15%) closed this week down 12.6% for the week, after being down as much as 18.3% for the week, according to data provided by S&P Global Market Intelligence ... louisiana dental insurance planstrading options with dollar100 Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ... Dec 4, 2023 · Castle Biosciences Price Performance. NASDAQ CSTL traded up $0.07 during trading on Monday, reaching $20.04. The company’s stock had a trading volume of 33,667 shares, compared to its average ... noc analyst Jun 5, 2023 · Castle Biosciences (CSTL) In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Castle Biosciences, with a price target of $38.00 . The company’s shares closed last ... Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ...